Senescent Mesenchymal Stem Cell Identification via Telomere and Gene Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying senescent mesenchymal stem cells in vitro cultures are inadequate, leading to genetic instability and reduced biomedical utility due to oxidative stress and prolonged culture periods, which can result in chromosomal abnormalities and altered gene expression patterns.
Innovation Solution
A method involving the measurement of telomere length, ploidy levels, detection of multipolar mitosis, and expression analysis of specific genes (SCIN, EDN-1, AKAP9, CXCL12, CXCL1, and CD70) to identify senescent mesenchymal stem cells, enabling the selection of genetically stable cells for cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If mesenchymal stem cells are expanded in in vitro culture for 4 to 8 weeks to achieve sufficient cell numbers for therapy, then the quantity of cells increases, but genetic instability and chromosomal abnormalities occur due to oxidative stress and prolonged culture
Solution Approach 1:
The patent applies preliminary action by establishing a comprehensive identification method using multiple biomarkers (telomere length, ploidy levels, multipolar mitosis detection, and gene expression analysis) before cell therapy implementation. This allows early detection of senescent cells and genetic instability markers, enabling selection of genetically stable cell populations for therapeutic use, thus preventing the propagation of unstable cells through the culture expansion process
Solution Approach 2:
The patent employs parameter changes by monitoring and analyzing multiple physiological and genetic parameters simultaneously (telomere length, ploidy levels, mitotic spindle configuration, and expression levels of specific genes). By tracking these parameter changes during culture expansion, the method identifies senescent cells and enables selection of cells that maintain genetic stability throughout the expansion process
2Productivity
If pre-oxidising conditions (20% O2) and increased concentrations of saline and glucose are used during culture, then cell proliferation is enhanced, but mutations and chromosomal abnormalities increase putting biosafety at risk
Solution Approach 1:
The patent applies feedback by using the identified biomarkers (telomere length, ploidy levels, multipolar mitosis, gene expression) to monitor the physiological state of cells during culture expansion. This feedback mechanism allows assessment of oxidative stress damage and genetic instability, enabling adjustment of culture conditions or selection of cells that have resisted oxidative damage, thus maintaining biosafety while achieving sufficient proliferation
3Ease of operation
If current identification methods are used for senescent cells, then the detection process is simple, but genetic instability is not adequately detected leading to reduced biomedical utility
Solution Approach 1:
The patent applies merging by combining multiple detection approaches into a unified identification method. Instead of relying on a single simple marker, the patent integrates telomere length measurement, ploidy level determination, multipolar mitosis detection, and gene expression analysis. This combination provides comprehensive and accurate senescence detection while maintaining operational feasibility through standardized protocols
Data Source
Figure 1A~1B
Figure 1C~2
Figure 3~4
AI summary
The invention refers to a method for identifying senescent mesenchymal stem cells growing in in vitro culture, comprising: measuring the length of telomeres of the chromosomes, determining the level of ploidy in the cell, detecting the presence of multipolar mitosis and determining the level of expression of the genes SCIN, AKAP9, EDN-1, CXCL1, CXCL12 and/or CD70. This method can be of use for carrying out studies of genetic stability in mesenchymal stem cell cultures, enabling identification and selection of the most stable and appropriate cells to be employed in cell therapy.